NBSE vs. INM, LSDI, PBLA, ATNF, BDRX, GRI, PRFX, ALLR, QLGN, and PXMD
Should you be buying NeuBase Therapeutics stock or one of its competitors? The main competitors of NeuBase Therapeutics include InMed Pharmaceuticals (INM), Lucy Scientific Discovery (LSDI), Panbela Therapeutics (PBLA), 180 Life Sciences (ATNF), Biodexa Pharmaceuticals (BDRX), GRI Bio (GRI), PainReform (PRFX), Allarity Therapeutics (ALLR), Qualigen Therapeutics (QLGN), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical preparations" industry.
InMed Pharmaceuticals (NASDAQ:INM) and NeuBase Therapeutics (NASDAQ:NBSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
NeuBase Therapeutics received 41 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 60.49% of users gave NeuBase Therapeutics an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.4% of NeuBase Therapeutics shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of NeuBase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
NeuBase Therapeutics has lower revenue, but higher earnings than InMed Pharmaceuticals.
NeuBase Therapeutics has a net margin of 0.00% compared to NeuBase Therapeutics' net margin of -115.76%. NeuBase Therapeutics' return on equity of -54.31% beat InMed Pharmaceuticals' return on equity.
In the previous week, NeuBase Therapeutics had 2 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 4 mentions for NeuBase Therapeutics and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.97 beat NeuBase Therapeutics' score of 0.44 indicating that NeuBase Therapeutics is being referred to more favorably in the news media.
InMed Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, NeuBase Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Summary
NeuBase Therapeutics beats InMed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get NeuBase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuBase Therapeutics Competitors List
Related Companies and Tools
